| Systematic (IUPAC) name | |
|---|---|
| 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Pharmacokinetic data | |
| Bioavailability | 34% |
| Protein binding | 69% |
| Half-life | 1.8h |
| Identifiers | |
| CAS number | 748806-39-5 |
| ATC code | None |
| Chemical data | |
| Formula | C21H23ClN6 |
| Mol. mass | 394.91 |
| (what is this?) (verify) |
|
PF-184563 is a potent, selective non-peptidic antagonist of the V1a receptor.[1]. The compound was discovered by Pfizer in its Sandwich, Kent research center, as a potential treatment for dysmenorrhoea, an indication for which V1a antagonists have shown efficacy.[2].
|
||||||||||||||||||||||||||||||||||